Bajorin D F, Bosl G J, Alcock N W, Niedzwiecki D, Gallina E, Shurgot B
Cancer Res. 1986 Nov;46(11):5969-72.
Nephrotoxicity, the dose-limiting toxicity of cis-diamminedichloroplatinum(II) (CDDP), is ameliorated when administered in hypertonic saline with normal saline hydration. To determine whether the diminished nephrotoxicity is associated with alteration of the pharmacokinetics of CDDP, we examined the pharmacokinetics of free and total platinum, platinum renal excretion, and urine electrolytes in patients given CDDP in hypertonic saline and in patients given CDDP in a conventional manner. The pharmacokinetics of free and total platinum for equal doses of CDDP were similar regardless of the vehicle of administration and the method of hydration. CDDP given in a vehicle of high chloride concentration with normal saline hydration resulted in a statistically significant increase in both urine volume and chloruresis compared to the conventional regimen. The decreased nephrotoxicity associated with administration of CDDP in hypertonic saline with saline diuresis may be related to increased chloruresis, urinary volume, or a combination of both, but did not appear to be related to an alteration in the pharmacokinetics.
肾毒性是顺二氯二氨铂(CDDP)的剂量限制性毒性,当在高渗盐水中给药并补充生理盐水时,肾毒性会减轻。为了确定肾毒性降低是否与CDDP药代动力学改变有关,我们研究了在高渗盐水中接受CDDP治疗的患者以及以传统方式接受CDDP治疗的患者中游离铂和总铂的药代动力学、铂的肾脏排泄及尿液电解质情况。无论给药载体和补液方法如何,等量CDDP的游离铂和总铂药代动力学相似。与传统给药方案相比,在高氯浓度载体中给予CDDP并补充生理盐水会使尿量和尿氯排泄在统计学上显著增加。在高渗盐水中给予CDDP并进行盐水利尿时肾毒性降低,可能与尿氯排泄增加、尿量增加或两者共同作用有关,但似乎与药代动力学改变无关。